Immunovant, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Immunovant, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2019 to Q2 2024.
  • Immunovant, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending June 30, 2024 was $686K, a 22.9% decline year-over-year.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $472M, a 566% increase from 2022.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $70.9M, a 64.6% decline from 2021.
  • Immunovant, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $200M, a 47.8% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $686K -$204K -22.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q2 2023 $890K +$869K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q2 2022 $21K* -$70K Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q2 2021 $91K -$193M -100% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q2 2020 $194M +$188M +3550% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q2 2019 $5.3M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$177K Jan 1, 2019 Mar 31, 2019 10-Q 2019-06-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.